Literature DB >> 6993570

Human graft versus host disease.

R Parkman, J Rappeport, F Rosen.   

Abstract

Human graft versus host disease is composed of 2 distinct clinical entities, acute graft versus host disease and chronic graft versus host disease, which have different pathogenesis. Acute graft versus host disease is produced by the attack of donor immunocompetent T or null lymphocytes against recipient histocompatibility antigens. The null lymphocytes may attack antigens shared by the donor and recipient and are autocytotoxic lymphocytes which can produce acute graft versus host disease in recipients of identical twin transplants. The cessation of acute graft versus host disease occurs when suppressor lymphocytes appear in the recipient's peripheral circulation. Chronic graft versus host disease is produced by immunocompetent lymphocytes that differentiate in the recipient. Its control is unknown. Some patients with chronic graft versus host disease have in vivo activated suppressor lymphocytes which produce a secondary immunoincompetence and an increased susceptibility to bacterial sepsis and death.

Entities:  

Mesh:

Year:  1980        PMID: 6993570     DOI: 10.1111/1523-1747.ep12543412

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

1.  T lymphocytes expressing HECA-452 epitope are present in cutaneous acute graft-versus-host disease and erythema multiforme, but not in acute graft-versus-host disease in gut organs.

Authors:  R E Davis; B R Smoller
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

2.  Lymphopenia and abnormal balance of T-lymphocyte subpopulations in toxic epidermal necrolysis.

Authors:  J C Roujeau; S Moritz; J C Guillaume; C Bombal; J Revuz; B Weil; R Touraine
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

3.  Graft-vs.-host-associated immune suppression is activated by recognition of allogeneic murine I-A antigens.

Authors:  G M Shearer; R B Levy
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.